Combination Therapy with Interferon-?? and Ribavirin for Hepatitis C
- 1 January 2001
- journal article
- Published by Springer Nature in BioDrugs
- Vol. 15 (4) , 225-238
- https://doi.org/10.2165/00063030-200115040-00003
Abstract
Combination therapy with ribavirin and interferon (IFN)-α for 6 to 12 months is currently the treatment of choice for chronic hepatitis C infection. The overall sustained response rate to treatment, defined as loss of hepatitis C virus (HCV) from serum 6 months after completion of treatment, is 40%. The indications for treatment are serum HCV RNA positivity, abnormal serum transaminases and the presence of portal fibrosis and/or moderate/severe inflammation.Keywords
This publication has 39 references indexed in Scilit:
- Recurrent autoimmune hepatitis after liver transplantation—when non-self becomes selfHepatology, 2000
- The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis CHepatology, 2000
- Efficacy and safety of combination therapy with interferon-α2b and ribavirin for chronic hepatitis C in HIV-infected patientsAIDS, 2000
- Standardization of hepatitis C virus-RNA quantification: Advances and unfinished businessHepatology, 2000
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- A randomized trial of ribavirin and interferon-α vs. interferon-α alone in patients with chronic hepatitis C who were non-responders to a previous treatmentPublished by Elsevier ,1999
- EASL International Consensus Conference on Hepatitis C Paris, 26–28 February 1999Journal of Hepatology, 1999
- Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α TherapyScience, 1998
- Neurovisual impairment: A frequent complication of alpha-interferon treatment in chronic viral hepatitisHepatology, 1998
- Interferon-α Induced Thyroid Dysfunction: Three Clinical Presentations and a Review of the LiteratureThyroid®, 1997